This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
Stocks Under $10 with 50-100% upside potential - 14 days FREE!

Oramed Pharmaceuticals To Present At The 12th Annual Diabetes Technology Society Meeting In Bethesda, MD, Nov 8-10, 2012

JERUSALEM, November 7, 2012 /PRNewswire/ --

Oramed Pharmaceuticals Inc. (OTCBB: ORMP; www.oramed.com), a developer of oral delivery systems, announced today that results of a study performed using its oral insulin formulation, ORMD-0801, have been accepted for presentation at the 12th Annual Diabetes Technology Society Meeting.  The abstract, titled "Concomitant oral and subcutaneous insulin therapy toward stabilization of uncontrolled T1DM," will be presented by Oramed's Chief Scientific Officer, Dr. Miriam Kidron, during the poster session being held from 4pm to 6:30pm (EST), on Thursday, November 8th. The meeting will take place at the Bethesda North Marriott Hotel & Conference Center.

Type 1 Diabetes Mellitus (T1DM), formerly known as juvenile diabetes, affects both young and adult populations. T1DM makes up approximately 5-10% of diabetes cases, and approximately $2 billion of the estimated $15 billion global insulin market. In this form of the disease, an autoimmune reaction destroys the body's insulin-producing cells in the pancreas making its patients completely dependent upon insulin from an external source.

T1DM is occasionally associated with instability and unpredictability of glycemic readings, resulting in poor control of blood sugar.  In severe cases, this condition has a disruptive impact on patient quality of life, due to inadequate clinical solutions. The study to be presented at the Diabetes Technology Society Meeting, and conducted in 2010, evaluated the safety and stabilizing potential of concomitant oral and subcutaneous insulin therapy in volunteers diagnosed with unstable T1DM. Concomitant administration of Oramed's oral insulin formulation, ORMD-0801, and subcutaneous insulin proved safe and well tolerated.  In addition, support with ORMD-0801 led to more frequent blood glucose readings within the healthy range (< 70 mg/dL) and to fewer readings within the high-risk zone (> 200 mg/dL). 

1 of 2

Select the service that is right for you!

COMPARE ALL SERVICES
Action Alerts PLUS
Try it NOW

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!
DOW 17,113.54 +61.81 0.36%
S&P 500 1,983.53 +9.90 0.50%
NASDAQ 4,456.0160 +31.3120 0.71%

Brokerage Partners

Rates from Bankrate.com

  • Mortgage
  • Credit Cards
  • Auto
Advertising Partners

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs